Menu
Share this

PPD Names Proven Leader for GMP Laboratory Services

Jon Denissen will oversee labs in U.S. and Europe

02 Apr. 2015

RSS

WILMINGTON, N.C., (April 2, 2015) – Pharmaceutical Product Development, LLC (PPD) today announced it has appointed Jon Denissen, Ph.D., as vice president of good manufacturing practices (GMP) laboratories. Denissen brings over 25 years of experience in the pharmaceutical and contract research organization (CRO) industries. He is based in PPD’s GMP lab facility in Middleton, Wisconsin.

“Jon’s experience includes successfully leading scientific teams and building effective client relationships that facilitate research collaboration,” said David Johnston, Ph.D., executive vice president of global laboratory services for PPD. “Our GMP laboratories provide fully integrated laboratory services for all phases of drug development, and Jon’s leadership will help drive PPD’s client-centric, quality-focused culture.”

PPD’s GMP laboratories, located in Middleton, Wisconsin, and Athlone, Ireland, conduct testing for clinical programs and marketed programs spanning all phases of drug development, and support PPD’s global laboratory operations. GMP laboratories play a key role in the company’s capabilities, which include exceptional scientific expertise, broad therapeutic experience and state-of-the-art facilities and instrumentation, which combine to deliver best-in-class laboratory services.

Prior to joining PPD, Denissen held senior leadership positions within the CRO industry and several positions of increasing responsibility at Abbott Laboratories, supporting drug discovery and development programs.

He earned his bachelor’s degree in chemistry from the University of Wisconsin-Madison and completed his doctorate in organic chemistry at the University of Illinois.

About PPD

PPD is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 13,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.

PPD Contacts

Media:
Elizabeth Humphrey
+1 910 558 6096
elizabeth.humphrey@ppdi.com

Investors:
Nate Speicher
+1 910 558 6783
nate.speicher@ppdi.com

Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about the appointment of Jon Denissen, Ph.D., and the future performance of PPD’s GMP laboratory unit, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: the ability to attract, integrate, retain and train key personnel; risks associated with and dependence on strategic relationships; risks associated with acquisitions and investments; competition in the outsourcing industry; PPD’s ability to win new business; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; consolidation in the pharmaceutical and biotechnology industries; rapid technological advances that make our services or capabilities less competitive; the ability to control SG&A spending; compliance with drug development regulations; changes in the regulation of the drug development process; and actual operating performance. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.

Contact Us

Media Contacts:

Randy Buckwalter Senior Manager, Corporate Communications
PPD
Tel: +1 919 456 4425

Elizabeth Humphrey Corporate Communications Manager
PPD
Tel: +1 910 558 6096

Contact Legal Notices Modern Slavery Transparency Statement Privacy Policy

© 2017 Pharmaceutical Product Development, LLC. All rights reserved.